Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Journey Medical Corp (DERM)

Journey Medical Corp (DERM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 202,163
  • Shares Outstanding, K 27,136
  • Annual Sales, $ 56,130 K
  • Annual Income, $ -14,670 K
  • EBIT $ -3 M
  • EBITDA $ 0 M
  • 60-Month Beta 0.81
  • Price/Sales 2.80
  • Price/Cash Flow N/A
  • Price/Book 7.85

Options Overview Details

View History
  • Implied Volatility 583.28% (-27.08%)
  • Historical Volatility 42.39%
  • IV Percentile 71%
  • IV Rank 87.84%
  • IV High 618.84% on 11/13/25
  • IV Low 326.44% on 12/17/25
  • Expected Move (DTE 9) 0.47 (6.23%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 380
  • Volume Avg (30-Day) 69
  • Put/Call OI Ratio 34.00
  • Today's Open Interest 105
  • Open Int (30-Day) 44
  • Expected Range 7.03 to 7.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.01
  • Low Estimate -0.10
  • Prior Year 0.08
  • Growth Rate Est. (year over year) -162.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.97 +7.60%
on 01/05/26
8.53 -12.08%
on 12/09/25
-0.43 (-5.42%)
since 12/05/25
3-Month
6.91 +8.54%
on 10/14/25
9.40 -20.21%
on 11/12/25
-0.05 (-0.66%)
since 10/07/25
52-Week
3.54 +112.16%
on 01/22/25
9.40 -20.21%
on 11/12/25
+3.39 (+82.48%)
since 01/07/25

Most Recent Stories

More News
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on...

FBIO : 4.27 (+1.43%)
DERM : 7.50 (+3.88%)
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold...

FBIO : 4.27 (+1.43%)
DERM : 7.50 (+3.88%)
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused...

FBIO : 4.27 (+1.43%)
DERM : 7.50 (+3.88%)
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions...

FBIO : 4.27 (+1.43%)
DERM : 7.50 (+3.88%)
Journey Medical Corporation to Participate in October 2025 Investor Conferences

SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused...

FBIO : 4.27 (+1.43%)
DERM : 7.50 (+3.88%)
Journey Medical Corporation to Participate in September 2025 Investor Conferences

SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused...

FBIO : 4.27 (+1.43%)
DERM : 7.50 (+3.88%)
Journey Medical Corporation to Present at the Emerging Growth Conference

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company...

FBIO : 4.27 (+1.43%)
DERM : 7.50 (+3.88%)
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000®...

FBIO : 4.27 (+1.43%)
DERM : 7.50 (+3.88%)
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical...

FBIO : 4.27 (+1.43%)
DERM : 7.50 (+3.88%)
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...

FBIO : 4.27 (+1.43%)
DERM : 7.50 (+3.88%)

Business Summary

Journey Medical Corporation is a commercial-stage pharmaceutical company. It focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Journey Medical Corporation is based in Scottsdale, Arizona.

See More

Key Turning Points

3rd Resistance Point 7.91
2nd Resistance Point 7.73
1st Resistance Point 7.61
Last Price 7.50
1st Support Level 7.32
2nd Support Level 7.14
3rd Support Level 7.02

See More

52-Week High 9.40
Last Price 7.50
Fibonacci 61.8% 7.16
Fibonacci 50% 6.47
Fibonacci 38.2% 5.78
52-Week Low 3.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar